GlassScriptPhysician profile
Reagan Hahn
NPI 1295376325
$12,715.87
in general payments reported to CMS, 2019-2025
33 companies · $1,735 in 2025
The $1,735 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $3,319 · 2023: $4,116 · 2024: $3,546 · 2025: $1,735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,292 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,291.76 |
| Education | $105.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,923.74 | 2022-2025 | |
| Ucb, INC. | $1,719.65 | 2022-2025 | Cimzia, Briviact, Bimzelx |
| Astrazeneca Pharmaceuticals LP | $1,183.64 | 2022-2025 | Saphnelo |
| Amgen INC. | $1,096.73 | 2022-2025 | Enbrel, Evenity, Tavneos |
| Janssen Biotech, INC. | $997.55 | 2022-2025 | Tremfya, Simponi Aria |
| Lilly USA, LLC | $679.19 | 2022-2024 | Taltz |
| Novartis Pharmaceuticals Corporation | $596.37 | 2022-2025 | |
| Pfizer INC. | $586.67 | 2022-2025 | |
| Radius Health, INC. | $461.20 | 2023-2025 | Tymlos |
| Mallinckrodt Hospital Products INC. | $429.49 | 2022-2025 | Acthar |
| Genzyme Corporation | $400.90 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $383.76 | 2022-2025 | Lupkynis |
| Ani Pharmaceuticals, INC. | $233.42 | 2022-2025 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $215.36 | 2022-2025 | Strensiq |
| Glaxosmithkline, LLC. | $105.04 | 2024-2025 | Benlysta |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.81 | 2023-2024 | Cyltezo |
| E.R. Squibb & Sons, L.L.C. | $57.34 | 2024-2025 | Orencia, Sotyktu |
| Fresenius Kabi USA, LLC | $46.36 | 2024-2025 | Idacio |
| Almatica Pharma LLC | $45.87 | 2025 | Teriparatide |
| Organon LLC | $45.21 | 2025 | Hadlima, Renflexis |
| Alvogen INC | $43.88 | 2023-2025 | Teriparatide |
| Kyowa Kirin, INC. | $41.45 | 2024 | Crysvita |
| Actelion Pharmaceuticals US, INC. | $39.37 | 2022 | |
| Sandoz INC. | $39.09 | 2023-2024 | Hyrimoz |
| Sobi, INC | $39.03 | 2022-2023 | |
| Tersera Therapeutics LLC | $36.73 | 2023 | Quzyttir |
| Celltrion USA INC. | $36.29 | 2023 | Yuflyma |
| Octapharma USA, INC. | $35.98 | 2022 | |
| Mylan Institutional INC. | $35.13 | 2023 | |
| Kiniksa Pharmaceuticals, LTD. | $24.27 | 2023 | Arcalyst |
| Ultragenyx Pharmaceutical INC. | $18.32 | 2024 | Crysvita |
| Depuy Synthes Sales INC. | $15.14 | 2022 | |
| Athena Bioscience, LLC | $10.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reagan Hahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.